Skip to Content

Elotuzumab use while Breastfeeding

Drugs containing Elotuzumab: Empliciti

Medically reviewed by Drugs.com. Last updated on April 24, 2021.

Elotuzumab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of elotuzumab during breastfeeding. Because elotuzumab is a large protein molecule with a molecular weight of 148,100 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. However, elotuzumab is administered with dexamethasone and lenalidomide, two drugs that have no information on use in nursing mothers. The manufacturer recommends that women receiving elotuzumab should not breastfeed.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Elotuzumab

CAS Registry Number

915296-00-3

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Antineoplastic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.